
All calories inside a 6-hour window each day, where a longer overnight fast lets insulin and blood sugar drop and aligns eating with the hours when the body handles fuel most efficiently.
18:6 TRE with graded starter windows is best framed as a safety-screened personal experiment for medically stable adults, testing weight, glucose, blood pressure, waist, hunger, energy, and tolerability while logging adherence as interpretation context.
The direct 6-hour evidence base is relevant but small, short-term, and selected-population. Adjacent-window, calorie-confounding, behavioral, clinical, safety-only, mechanistic, observational, registry, and protocol-only sources should remain separate evidence groups so the page does not convert context into direct 18:6 proof.
Many sources are adjacent variants or safety/context records. Effects may depend on total energy intake, protein/fiber, diet quality, adherence, body composition, timing, clinical population, and medication status.
Sources checked is every card shown on this page. Direct human participants counts only primary human studies with coded participant totals, deduplicated by cohort when possible. Review cards may show larger pooled head counts on their own rows, and those pooled totals are treated as approximate rather than added into the page-level number.
Direct 6-hour studies are relevant for this 18:6 target, but they are short-term and include selected, supervised, young-adult, overweight, obesity, or prediabetes populations. They support possible short-term weight or selected metabolic signals while also preserving sleep-null and mechanistic boundaries.
8 sources · 6 trials · 2 physiology studies
An 8-week RCT directly tested early and later 6-hour TRE windows in overweight or obese young adults.
An 8-week free-living RCT included a direct 6-hour TRF arm and found weight and cardiometabolic improvements versus control.
Four days of supervised 08:00-14:00 eTRF improved 24-hour glucose metrics but remains acute mechanism evidence.
Five weeks of supervised 6-hour early TRF improved insulin, blood-pressure, oxidative-stress, and appetite endpoints without intended weight loss.
A small college-student pilot directly tested a 6-hour early eating window but had major feasibility caveats.
Acute 6-hour early TRF reduced appetite-related signals and increased fat-oxidation markers but did not raise 24-hour energy expenditure.
A direct 6-hour TRF sleep analysis found no clear sleep-quality or sleep-duration advantage.
A 2025 crossover trial directly compared early and delayed 6-hour TRE windows in untrained adults.
Starter windows, adherence tracking, and real-world barriers are implementation context. The 12:12 to 14:10 to 16:8 to 18:6 ramp and the 4-target-day analysis threshold are Murph operational scaffolds, not evidence-derived optimal dosing.
8 sources · 3 trials · 3 reviews · 2 supporting sources
App-based tracking found long, erratic eating windows and showed feasibility of reducing very long windows to 10–12 h.
Use as adherence-context evidence: work, social, and family constraints should be expected and personalized starter windows are likely necessary.
TRE mechanisms/translation review supports graded implementation rationale.
Window-specific TRF review supports flexibility and uncertainty about optimal timing.
TRE adherence reporting is inconsistent, and social, family, work, and monitoring burdens are often underreported.
Three 8-hour schedule options were feasible, but early timing appeared harder to sustain.
App-supported 10-hour TRE compressed eating windows and produced pilot weight/BP signals.
In healthy adults, 16:8 changed body composition while 12:12 and 14:10 did not clearly do so.
Adjacent 8-hour, 16:8, calorie-restricted, isocaloric, NAFLD, synthesis, and calorie-confounding sources prevent overclaiming. They support expectation-setting that TRE may not outperform calorie restriction, usual timing, or calorie-controlled comparators.
9 sources · 6 trials · 3 reviews
TRE did not add clear NAFLD benefit beyond daily calorie restriction.
A three-arm RCT found no significant weight or metabolic advantage for self-selected 8-hour TRE.
Adding 8-hour TRE to calorie restriction did not clearly outperform calorie restriction alone.
Isocaloric TRE did not outperform usual eating for weight or glucose outcomes.
TRE benefits may be driven more by energy deficit than timing alone.
TRE weight effects differ by calorie-control design and include fat-free-mass changes.
Cochrane intermittent-fasting review is a conservative context source, not direct 18:6 evidence.
The TREAT 16:8 RCT did not show clear weight or cardiometabolic advantage over control.
An 8-hour early TRE plus calorie-restriction RCT improved weight but does not directly test 18:6.
Qualitative, appetite, and behavioral sources support tracking hunger, social disruption, binge-restrict patterns, adherence burden, and reasons to step back to a wider eating window.
5 sources · 3 reviews · 2 supporting sources
TRE can increase hunger versus isocaloric controls.
TRE may increase bedtime hunger while disordered-eating questionnaire results are mostly null but not risk-free.
Use as adjacent-variant behavioral evidence: TRE adherence depends on schedule fit, social context, hunger/energy response, support, and whether monitoring feels helpful rather than burdensome.
Use as adjacent behavioral evidence: simplicity and flexibility can support adherence, but hunger/cravings, obsessive thinking, conflicting schedules, and social eating can require coping strategies and off-ramps.
Fasting can be a headache or migraine trigger for susceptible users, so headaches should be explicit TRE tolerability signals.
Type 2 diabetes, metabolic syndrome, Ramadan diabetes guidance, and hypoglycemia sources are clinical-context and medication-safety boundaries. They should not be used as general consumer 18:6 efficacy or broad safety proof.
6 sources · 3 trials · 2 guidance sources · 1 observational study
8-hour TRE helped weight and HbA1c in supervised adults with type 2 diabetes, but medication context limits directness.
EPIDIAR documents increased severe hypoglycemia during Ramadan among people with diabetes.
Use as adjacent clinical RCT evidence: personalized 8- to 10-hour TRE can improve some glycemic and body-composition endpoints in metabolic syndrome, but population and window differ from 18:6 starter protocols.
Diabetes fasting requires medication-specific clinical planning, especially for insulin and sulfonylurea users.
NCBI Ramadan diabetes reference gives concrete monitoring and break-fast safety thresholds.
A 10-hour metabolic-syndrome pilot reported weight, BP, lipid, and HbA1c improvements.
Pregnancy, eating-disorder vulnerability, youth, athlete low-energy availability, gallbladder-risk, and broad adverse-event sources support clinician-guidance or exclusion language rather than claims of safety in those groups.
6 sources · 3 reviews · 2 guidance sources · 1 observational study
Adolescent fasting predicted binge/bulimic pathology over five years.
NICE NG69 is a core eating-disorder contraindication and referral source.
IOC REDs consensus anchors athlete low-energy-availability boundaries.
Pregnancy fasting evidence has no consensus guideline and gaps for rare but serious outcomes, so it should remain a medical-supervision boundary.
Common adverse events were not significantly higher with intermittent fasting in overweight/obesity RCTs, but dizziness and special-population boundaries remain important.
Rapid weight loss and prolonged fasting are gallstone-risk contexts, creating a gallbladder safety boundary for TRE protocols.
Protocol-only, registry, and observational cardiovascular sources are context. They should be used to avoid long-term safety or longevity overclaims and not as causal evidence for or against a monitored short self-experiment.
3 sources · 1 trial · 1 observational study · 1 supporting source
A direct 18:6 T2D study protocol defines a clinically supervised 14:00–20:00 eating window.
Observational NHANES analysis reports a cardiovascular-mortality association for <8-hour eating duration.
8-hour time-restricted eating linked to a 91% higher risk of cardiovascular death